Literature DB >> 25968175

An epidemiological model for prediction of endometrial cancer risk in Europe.

Anika Hüsing1, Laure Dossus2,3,4, Pietro Ferrari5, Anne Tjønneland6, Louise Hansen6, Guy Fagherazzi2,3,4, Laura Baglietto7,8, Helena Schock9, Jenny Chang-Claude10, Heiner Boeing11, Annika Steffen11, Antonia Trichopoulou12,13, Christina Bamia14, Michalis Katsoulis12, Vittorio Krogh15, Domenico Palli16, Salvatore Panico17, N Charlotte Onland-Moret18,19, Petra H Peeters18,19, H Bas Bueno-de-Mesquita19,20,21, Elisabete Weiderpass22,23,24,25, Inger T Gram22, Eva Ardanaz26,27, Mireia Obón-Santacana28, Carmen Navarro27,29,30, Emilio Sánchez-Cantalejo27,31, Nerea Etxezarreta27,32, Naomi E Allen33, Kay Tee Khaw34, Nick Wareham35, Sabina Rinaldi5, Isabelle Romieu5, Melissa A Merritt19, Marc Gunter19, Elio Riboli19, Rudolf Kaaks9.   

Abstract

Endometrial cancer (EC) is the fourth most frequent cancer in women in Europe, and as its incidence is increasing, prevention strategies gain further pertinence. Risk prediction models can be a useful tool for identifying women likely to benefit from targeted prevention measures. On the basis of data from 201,811 women (mostly aged 30-65 years) including 855 incident EC cases from eight countries in the European Prospective Investigation into Cancer and Nutrition cohort, a model to predict EC was developed. A step-wise model selection process was used to select confirmed predictive epidemiologic risk factors. Piece-wise constant hazard rates in 5-year age-intervals were estimated in a cause-specific competing risks model, five-fold-cross-validation was applied for internal validation. Risk factors included in the risk prediction model were body-mass index (BMI), menopausal status, age at menarche and at menopause, oral contraceptive use, overall and by different BMI categories and overall duration of use, parity, age at first full-term pregnancy, duration of menopausal hormone therapy and smoking status (specific for pre, peri- and post-menopausal women). These variables improved the discriminating capacity to predict risk over 5 years from 71% for a model based on age alone to 77% (overall C statistic), and the model was well-calibrated (ratio of expected to observed cases = 0.99). Our model could be used for the identification of women at increased risk of EC in Western Europe. To achieve an EC-risk model with general validity, a large-scale cohort-consortium approach would be needed to assess and adjust for population variation.

Entities:  

Keywords:  Endometrial cancer; Epidemiology; Prevention; Risk model

Mesh:

Year:  2015        PMID: 25968175     DOI: 10.1007/s10654-015-0030-9

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  30 in total

1.  Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

Review 2.  Capacity of endometrial thickness measurement to diagnose endometrial carcinoma in asymptomatic postmenopausal women: a systematic review and meta-analysis.

Authors:  M C Breijer; J A H Peeters; B C Opmeer; T J Clark; R H M Verheijen; B W J Mol; A Timmermans
Journal:  Ultrasound Obstet Gynecol       Date:  2012-12       Impact factor: 7.299

Review 3.  Progesterone: the ultimate endometrial tumor suppressor.

Authors:  Shujie Yang; Kristina W Thiel; Kimberly K Leslie
Journal:  Trends Endocrinol Metab       Date:  2011-02-25       Impact factor: 12.015

4.  Incidence rates of endometrial hyperplasia, endometrial cancer and hysterectomy from 1980 to 2003 within a large prepaid health plan.

Authors:  James V Lacey; Victoria M Chia; Brenda B Rush; Danny J Carreon; Douglas A Richesson; Olga B Ioffe; Brigitte M Ronnett; Nilanjan Chatterjee; Bryan Langholz; Mark E Sherman; Andrew G Glass
Journal:  Int J Cancer       Date:  2012-03-14       Impact factor: 7.396

Review 5.  Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies.

Authors:  Andrew G Renehan; Margaret Tyson; Matthias Egger; Richard F Heller; Marcel Zwahlen
Journal:  Lancet       Date:  2008-02-16       Impact factor: 79.321

6.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors:  J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal:  Eur J Cancer       Date:  2013-02-26       Impact factor: 9.162

Review 7.  Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.

Authors:  Jason Chin; Justin C Konje; Martha Hickey
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

8.  European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection.

Authors:  E Riboli; K J Hunt; N Slimani; P Ferrari; T Norat; M Fahey; U R Charrondière; B Hémon; C Casagrande; J Vignat; K Overvad; A Tjønneland; F Clavel-Chapelon; A Thiébaut; J Wahrendorf; H Boeing; D Trichopoulos; A Trichopoulou; P Vineis; D Palli; H B Bueno-De-Mesquita; P H M Peeters; E Lund; D Engeset; C A González; A Barricarte; G Berglund; G Hallmans; N E Day; T J Key; R Kaaks; R Saracci
Journal:  Public Health Nutr       Date:  2002-12       Impact factor: 4.022

9.  Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort.

Authors:  Ian Jacobs; Aleksandra Gentry-Maharaj; Matthew Burnell; Ranjit Manchanda; Naveena Singh; Aarti Sharma; Andy Ryan; Mourad W Seif; Nazar N Amso; Gillian Turner; Carol Brunell; Gwendolen Fletcher; Rani Rangar; Kathy Ford; Keith Godfrey; Alberto Lopes; David Oram; Jonathan Herod; Karin Williamson; Ian Scott; Howard Jenkins; Tim Mould; Robert Woolas; John Murdoch; Stephen Dobbs; Simon Leeson; Derek Cruickshank; Steven J Skates; Lesley Fallowfield; Mahesh Parmar; Stuart Campbell; Usha Menon
Journal:  Lancet Oncol       Date:  2010-12-10       Impact factor: 41.316

10.  Anthropometric factors and risk of endometrial cancer: the European prospective investigation into cancer and nutrition.

Authors:  Christine Friedenreich; Anne Cust; Petra H Lahmann; Karen Steindorf; Marie-Christine Boutron-Ruault; Françoise Clavel-Chapelon; Sylvie Mesrine; Jakob Linseisen; Sabine Rohrmann; Heiner Boeing; Tobias Pischon; Anne Tjønneland; Jytte Halkjaer; Kim Overvad; Michelle Mendez; M L Redondo; Carmen Martinez Garcia; Nerea Larrañaga; María-José Tormo; Aurelio Barricarte Gurrea; Sheila Bingham; Kay-Tee Khaw; Naomi Allen; Tim Key; Antonia Trichopoulou; Effie Vasilopoulou; Dimitrios Trichopoulos; Valeria Pala; Domenico Palli; Rosario Tumino; Amalia Mattiello; Paolo Vineis; H Bas Bueno-de-Mesquita; Petra H M Peeters; Göran Berglund; Jonas Manjer; Eva Lundin; Annekatrin Lukanova; Nadia Slimani; Mazda Jenab; Rudolf Kaaks; Elio Riboli
Journal:  Cancer Causes Control       Date:  2007-02-12       Impact factor: 2.506

View more
  12 in total

1.  Feasibility of a reduced field-of-view diffusion-weighted (rFOV) sequence in assessment of myometrial invasion in patients with clinical FIGO stage I endometrial cancer.

Authors:  Priya Bhosale; Jingfei Ma; Revathy Iyer; Preetha Ramalingam; Wei Wei; Pamela Soliman; Michael Frumovitz; Vikas Kundra
Journal:  J Magn Reson Imaging       Date:  2015-07-16       Impact factor: 4.813

2.  Hsa_circ_0002577 promotes endometrial carcinoma progression via regulating miR-197/CTNND1 axis and activating Wnt/β-catenin pathway.

Authors:  Qiankun Shen; Tao He; Hongying Yuan
Journal:  Cell Cycle       Date:  2019-05-21       Impact factor: 4.534

3.  Hormonally Active Contraceptives, Part II: Sociological, Environmental, and Economic Impact.

Authors:  William V Williams; Joel Brind; Laura Haynes; Michael D Manhart; Hanna Klaus; Angela Lanfranchi; Gerard Migeon; Michael Gaskins; Elvis I Šeman; Lester Ruppersberger; Kathleen M Raviele
Journal:  Linacre Q       Date:  2021-04-21

4.  Cancer Progress and Priorities: Uterine Cancer.

Authors:  Ashley S Felix; Louise A Brinton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-09       Impact factor: 4.254

5.  Development and Validation of Lifestyle-Based Models to Predict Incidence of the Most Common Potentially Preventable Cancers.

Authors:  Juliet A Usher-Smith; Stephen J Sharp; Robert Luben; Simon J Griffin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-09-13       Impact factor: 4.254

Review 6.  Association of Combined Estrogen-Progestogen and Progestogen-Only Contraceptives with the Development of Cancer.

Authors:  William V Williams; Louise A Mitchell; S Kathleen Carlson; Kathleen M Raviele
Journal:  Linacre Q       Date:  2019-01-03

7.  Expression of NAD(P)H quinone dehydrogenase 1 (NQO1) is increased in the endometrium of women with endometrial cancer and women with polycystic ovary syndrome.

Authors:  William Atiomo; Mohamad Nasir Shafiee; Caroline Chapman; Veronika M Metzler; Jad Abouzeid; Ayşe Latif; Amy Chadwick; Sarah Kitson; Vanitha N Sivalingam; Ian J Stratford; Catrin S Rutland; Jenny L Persson; Niels Ødum; Pablo Fuentes-Utrilla; Jennie N Jeyapalan; David M Heery; Emma J Crosbie; Nigel P Mongan
Journal:  Clin Endocrinol (Oxf)       Date:  2017-08-18       Impact factor: 3.478

8.  Population-Based Screening for Endometrial Cancer: Human vs. Machine Intelligence.

Authors:  Gregory R Hart; Vanessa Yan; Gloria S Huang; Ying Liang; Bradley J Nartowt; Wazir Muhammad; Jun Deng
Journal:  Front Artif Intell       Date:  2020-11-24

9.  A guide for endometrial cancer cell lines functional assays using the measurements of electronic impedance.

Authors:  Joanna Kozak; Paulina Wdowiak; Ryszard Maciejewski; Anna Torres
Journal:  Cytotechnology       Date:  2017-10-07       Impact factor: 2.058

10.  circSLC6A6 Sponges miR-497-5p to Promote Endometrial Cancer Progression via the PI4KB/Hedgehog Axis.

Authors:  Juan Hu; Xing Peng; Weina Du; Yichuan Huang; Chun Zhang; Xian Zhang
Journal:  J Immunol Res       Date:  2021-06-22       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.